Journal
PHARMACOGENOMICS
Volume 11, Issue 6, Pages 809-841Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.10.70
Keywords
ABC; chemotherapy; nucleobase; nucleoside; pharmacogenetics; plasma membrane transporter; polymorphic variant; SLC
Categories
Funding
- CIBER (Instituto de Salud Carlos III) [SAF2008-00577]
- Generalitat de Catalunya [FIPSE 36621/06, 2009SGR624]
- Ministerio de Ciencia e Innovacion (MICINN)
Ask authors/readers for more resources
This article focuses on the different types of transporter proteins that have been implicated in the influx and efflux of nucleoside-derived drugs currently used in the treatment of cancer, viral infections (i.e., AIDS) and other conditions, including autoimmune and inflammatory diseases. Genetic variations in nucleoside-derived drug transporter proteins encoded by the gene families SLC15, SLC22, SLC28, SLC29, ABCB, ABCC and ABCG will be specifically considered. Variants known to affect biological function are summarized, with a particular emphasis on those for which clinical correlations have already been established. Given that relatively little is known regarding the genetic variability of the players involved in determining nucleoside-derived drug bioavailability, it is anticipated that major challenges will be faced in this area of research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available